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Abstract
Background: Treatment for localized soft tissue sarcoma includes surgery and radiation, while the role of
chemotherapy is controversial. Biomarkers that could predict therapeutic response or prognosticate overall survival (OS)
are needed to define patients most likely to benefit from systemic treatment. Serum protein acidic and rich in cysteine
(SPARC) is a matricellular glycoprotein that has been evaluated as a potential biomarker in numerous malignancies
given its involvement in cell adhesion, proliferation, migration, and tissue remodeling.
Methods: Using primary biopsy and resection specimens from patients with high-risk localized, soft tissue sarcoma
treated on a neo/adjuvant chemotherapy study, SPARC expression was assessed and compared to patient and tumor
characteristics, treatment, and outcomes. Survival functions were estimated using the Kaplan–Meier method and
compared using the log-rank test. The Cox model was used for multivariate analysis.
Results: Fifty patients had primary tumor specimens available. High, low, and no SPARC expression was found in 22,
13, and 15 patients, respectively. There was no significant difference in time to recurrence or OS between patients in
these three groups. Comparing lack of SPARC expression with any SPARC expression, there was no significant
difference in time to recurrence in patients without SPARC expression (n = 15) compared to patients with SPARC
expression (n = 35). Likewise, there was no statistically significant difference in OS in patients without SPARC expression
versus patients whose tumors expressed SPARC.
Conclusions: Although we did not find a statistically significant difference in time to recurrence and OS in patients
with high-risk soft tissue sarcoma, we did identify a trend toward improved time to recurrence and OS in patients
whose tumors lacked SPARC expression. However, SPARC did not demonstrate the ability to discern which high-risk
patients may have a worse prognosis or greater benefit from chemotherapy.
Trial registration: The trial was registered on September 13, 2005 with ClinicalTrials.gov, number https://clinicaltrials.
gov/ct2/show/NCT00189137?term=sarcoma&id=NCT00189137&state1=NA%3AUS%3AMI&phase=1&rank=1.
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Background
Sarcomas are a heterogeneous group of malignant tumors
of connective tissue and bone with a propensity for local
recurrence and distant metastases. Surgery and radiation
are the mainstays of treatment for localized disease while
the role of chemotherapy in this setting is controversial.
Novel biomarkers that could predict therapeutic response
to chemotherapy or that could prognosticate overall sur-
vival (OS) are needed to define the patients most likely to
benefit from systemic treatment.
Serum protein acidic and rich in cysteine (SPARC), also
known as osteonectin and BM-40, is a matricellular glyco-
protein that is secreted by tumor and/or surrounding
stroma. SPARC has been evaluated as a potential biomarker
in numerous malignancies given its involvement in cell
adhesion, proliferation, migration, and tissue remodeling
[1]. Studies in different cancer types have demonstrated
varying effects on tumorigenesis. For example, in ovarian
and colorectal cancer as well as neuroblastoma, SPARC has
demonstrated antitumorigenic properties inhibiting angio-
genesis and functioning as a tumor suppressor. Conversely,
in breast, melanoma, brain, colon, prostate, kidney, esopha-
geal, lung, and pancreatic cancers, SPARC expression has
been associated with a more aggressive phenotype, inhibit-
ing apoptosis and promoting tumor invasiveness and
metastases [2]. The reasons for these disparate results, even
within the same type of cancer, are unknown but may be
explained by different methodologies used to assess SPARC
expression as well as its complex biology. Studies that have
evaluated different types of specimens including cell lines,
xenografts, and patient samples could account for some
variability. Discrepancies may also be due to the reporting
of expression of tumoral versus stromal SPARC as the
protein may have differential effects depending on the site
of expression. Also, the peptides of SPARC that are present
and interacting with the tumor microenvironment could
account for the varying effects between cancer types [3].
The prognostic and predictive potential of SPARC in can-
cer is controversial. In one study of advanced pancreatic
cancer patients receiving gemcitabine and nab-paclitaxel,
high stromal SPARC expressers had a statistically signifi-
cant longer OS than low SPARC expressers on multivariate
analysis [4]. However, this finding was not confirmed on a
subsequent phase III study [5]. In resected pancreatic can-
cer, SPARC stromal and cytoplasmic overexpression was
associated with statistically significant worse disease-free
survival (DFS) and OS in those treated with adjuvant
gemcitabine, and not 5-fluorouracil, suggesting that SPARC
may have a role as a predictive marker [6].
In breast cancer, SPARC expression has largely been
associated with a more aggressive phenotype and an
unfavorable prognosis [7, 8]. In a large study of localized
breast cancer, pre-treatment core biopsies were analyzed
for SPARC expression by IHC. The highest expression
rates were seen in triple-negative tumors (TNBC). In the
overall population as well as in the TNBCs, high SPARC
expression was associated with a greater likelihood of
pathological complete response to neoadjuvant chemo-
therapy with docetaxel, doxorubicin, and cyclophospha-
mide +/- capecitabine and vinorelbine suggesting a role
as a predictive biomarker. There was no significant cor-
relation between SPARC expression and DFS or OS [9].
In sarcoma, SPARC has recently been suggested as a
potential prognostic factor in a relatively small study.
Twenty-seven sarcoma specimens were obtained at vary-
ing time points in the patients’ clinical courses and eval-
uated for SPARC expression. Staining intensity ranged
from 1+ (low) to 3+ (strong). Patients were identified as
high SPARC expressers if at least 50 % of the tumor cells
displayed 2+ staining (56 %). The other patients were
considered low SPARC expressers (44 %). SPARC levels
did not correlate with specific histologies but did correl-
ate with OS. Low SPARC expressers had a median sur-
vival of 22.1 months while in the high expressers, the
median survival was 4.4 months [10].
In this report, we sought to evaluate SPARC expres-
sion in a more uniform population of patients with high
risk soft tissue sarcoma. Specifically, we performed an
exploratory analysis of SPARC expression in patients
with available tumor specimens that were enrolled on a
randomized phase II study examining patient outcomes
from treatment with one of two neo/adjuvant chemo-
therapy regimens for soft tissue sarcoma, doxorubicin
and ifosfamide (AI) and gemcitabine and docetaxel
(GT). Using primary biopsy and resection specimens,
SPARC expression was evaluated in terms of patient and
tumor characteristics, treatment, and outcome including
OS and time to recurrent disease.
Methods
Study design
The associated phase II study was a randomized, open-
label clinical trial in adults with stage IIB or III (localized,
deep, >5 cm, high-grade) soft tissue sarcoma undergoing
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neo/adjuvant chemotherapy and evaluated the difference
in the hospitalization rate between patients treated with
the two regimens. Patients were randomized 1:1 to AI or
GT. From November 2004 until August 2012, eighty
patients were treated. Full study outcomes are reported
elsewhere [11]. The trial is registered with ClinicalTrials.
gov, number NCT00189137.
Archival tumor samples obtained as part of clinical
care, through core needle biopsy to establish diagnosis
or recurrence or at definitive surgery, were available
for 57 patients. All samples were formalin-fixed
paraffin-embedded. The samples were stored at the
University of Michigan. All patients provided written
informed consent to participate in the trial as well as
for correlative work done on tumor and serum samples
that were collected. The Institutional Review Board at
the University of Michigan approved this study.
Imunohistochemical staining of SPARC
Immunohistochemical staining (IHC) for SPARC was
performed on formalin fixed, paraffin sections cut at 5
microns and rehydrated with water. Heat induced epitope
retrieval was performed with FLEX TRS Low pH Retrieval
buffer (6.10) for 20 min (Dako, N.A., Carpinteria, CA).
After peroxidase blocking, the antibody SPARC (1B2)
mouse monoclonal (Novus Biologicals, Littleton, CO) was
applied at a dilution of 1:8000 at room temperature for
60 min. The FLEX HRP EnVision System (Dako N. A.)
was used for detection. DAB chromagen was then applied
for 10 min. Slides were counterstained with Harris
Hematoxylin for 5 s, dehydrated, and coverslipped.
Immunostaining results were evaluated and scored
by an expert sarcoma pathologist without knowledge
of the clinical outcomes of the patients. IHC cutoffs
for SPARC have not been established in sarcoma.
Previous evaluation of SPARC expression in sarcoma
has defined overexpression as a staining intensity of 2
+ and percentage of cells stained ranging from 30 to
50 % [10, 12]. IHC results in our study were also
assessed based upon staining intensity and percentage
of cells stained. Staining intensity was scored in four
levels, 0–3: 0 = none, 1 = weak, 2 = moderate, and 3 =
strong. The percentage of cells that stained was scored
0–3: 0 = 0 %, 1 = 1–10 %, 2 = 11–50 %, 3 > 50 %. The
individual scores were multiplied resulting in an
immunoreactivity score ranging from 0 to 9. The cut-
off for expression low versus high was chosen a priori
to avoid potential bias. A score ≥ 4 was considered
high and < 4 was low.
Statistical analysis
Time to recurrence was defined as time from surgical
resection to local or distant disease relapse. OS was defined
as time from study entry to death of any cause. Survival
functions were estimated using the Kaplan–Meier method
and compared using the log-rank test. The Cox model was
used for multivariate analysis. Clinicopathological variables
including age, sex, tumor size, tumor site, histology, and
chemotherapy regimen were included in the multivariate
model. P values <0.05 from a two-sided test were consid-
ered as statistically significant.
Results
There were 50 samples available from the primary
sarcoma diagnosis and 17 samples available from disease
recurrence. Ten patients had tumors from multiple time
points available for analysis. Patient and sarcoma charac-
teristics from the primary and recurrent tumors are
detailed in Table 1. The most common histology evalu-
ated in our study was undifferentiated pleomorphic
sarcoma, and the most common tumor location was the
extremity. Both primary and recurrent tumor samples
were evaluated; however, there were fewer recurrent
samples available for review limiting our statistical
analysis of these specimens. Of the primary tumors
examined, 49 were primary resection specimens, and
one was a core needle biopsy. Seven of these specimens
were obtained prior to chemotherapy, and the remaining
43 specimens were obtained after chemotherapy. Two
specimens were also evaluated after radiation therapy. In
the recurrent specimens, 13 specimens were obtained
prior to treatment for recurrent disease. Four were
obtained after chemotherapy had been administered.
High, low, and no SPARC expression was found in 22,
13, and 15 primary sarcomas, respectively (see Table 2)
and in 5, 4, and 8 recurrent sarcomas, respectively. Rep-
resentative images from the primary resection of patients
with leiomyosarcoma (no SPARC expression), malignant
peripheral nerve sheath tumor (low SPARC expression),
and myxofibrosarcoma (high SPARC expression) are
shown in Fig. 1. All patients had undergone chemother-
apy prior to their resection. HGUPS was the most
common histology treated in our study (n = 32), and
amongst those patients, SPARC expression level was
distributed throughout the groups with 50, 28, and 22 %
of tumors expressing high, low, and no SPARC.
Although limited numbers in other histologies, SPARC
expression was variable and showed no correlation with
subtype, with the exception of the three synovial
sarcoma specimens that all demonstrated a lack of
SPARC expression.
In the primary sarcoma specimens, more patients with
high SPARC expression had been pre-treated with GT,
while more patients with no or low SPARC expression
had been pretreated with AI. The best response to
chemotherapy is listed in Table 2. Most patients had
stable disease (SD) as their best response. There was no
significant difference in SPARC expression based upon
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best response to chemotherapy as evaluated by Response
Evaluation Criteria in Solid Tumors version 1.0
(RECIST) (data not shown).
In order to analyze time to recurrent disease and OS,
we divided the patients into two groups: those who
expressed SPARC and those who did not express SPARC.
In the primary tumor specimens, there was no statistically
significant difference in time to recurrent disease in
patients without SPARC expression (n = 15) than in those
patients whose tumors expressed SPARC (n = 35), see
Fig. 2. The 5 year relapse-free survival rates were 73 %
(0.44–0.89) and 56 % (0.37–0.71) in the absence and
presence of SPARC expression, respectively. Similarly,
there was no difference seen in terms of the OS in
sarcoma patients without SPARC expression compared to
sarcoma patients with SPARC expression, see Fig. 3. With
a median follow-up of 5 years, the median OS has not
been reached in either group. The 5 year OS rates were
87 % (0.56–0.94, 95%CI) and 66 % (0.47–0.80) in the
absence and presence of SPARC expression, respectively.
The effect of SPARC expression on time to recurrence
and OS was also not statistically significant when evalu-
ated using a multivariate analysis including age, sex, tumor
site, tumor histology, and chemotherapy regimen (see
Additional file 1: Tables S1 & S2).
Differences in SPARC expression over time were also
assessed for patients who had multiple tumor speci-
mens available. There were ten patients included in this
analysis. Six patients had no change in SPARC expres-
sion category (none, low, or high), although three of
these patients did have a change in score within the
same category. Three patients had a decrease in the
expression category while one patient demonstrated an








Median age in years (range) 61 (19–76) 50 (19–66)
Site of primary disease
Extremity 30 10
Trunk 19 7
Head & Neck 1 0







Leiomyosarcoma (LMS) 6 1
Liposarcoma (LPS) 6 1











Table 2 SPARC expression in the primary tumor
High SPARC Low SPARC No SPARC
Histology N = 22 N = 13 N = 15
UPS 16 9 7
LMS 2 2 2
LPS 3 1 2
Dedifferentiated 2 1 0
Pleomorphic/NOS 1 0 1
Myxoid 0 0 1
SS 0 0 3
MPNST 0 1 1
FS 1 0 0
Treatment for primary prior to tumor collection
Gemcitabine/docetaxel 14 3 3
Doxorubicin/ifosfamide 5 9 10
None 3 1 3
Radiation 0 1 1
% necrosis observed in tumor after chemotherapy
UPS 20–100 0–70 0–75
LMS 50 80a 30
LPS
Dedifferentiated 15–50 0 NA
Pleomorphic/NOS 85 NA 10
Myxoid NA NA 90
SS NA NA 0–80a
MPNST NA 5 40
FS 10 NA NA
Best Response to chemotherapy by RECIST 1.0
Partial response 0 2 0
Stable disease 19 8 14
Progressive disease 3 3 1
Recurrence 9 7 5
Local 2 4 0
Distant 7 3 5
aPt with 80 % necrosis had prior radiation
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increased expression category. These changes were not
statistically significant. See Table 3 for complete
characterization of these results.
Discussion
In this study, we analyzed SPARC expression in sarcoma
patients and found that 70 % of tumors demonstrated
some SPARC expression, including 44 % with high
SPARC expression. There was no statistically significant
difference seen in time to recurrence and OS in patients
whose tumor lacked SPARC expression versus those
who expressed SPARC.
While SPARC expression did not show a statistical
significant correlation with overall survival or disease
free survival, there was some difference noted. Our
results did show a trend similar to the Morgan et al.
sarcoma study which found that high SPARC expres-
sion was associated with a shorter OS than low SPARC
expression [10]. However, the magnitude of difference
was not nearly as robust as reported previously, even in
the absence of significance, and whether additional
patients or follow up time would have an impact on
this potential trend is unknown. All of our patients had
high-risk disease (stage IIB or III) as defined by widely
accepted clinical parameters including tumor size and
grade. This subset of sarcoma patients is at the highest
risk of metastases and thus is often considered for adju-
vant chemotherapy. Given the rarity, heterogeneity, and
lack of large, randomized studies in the disease, the role
of adjuvant chemotherapy in soft tissue sarcoma
remains controversial. Finding a prognostic biomarker
or a predictive factor of benefit for adjuvant therapy in
this group would be of great value in assisting clinicians
in making these difficult recommendations. While
SPARC expression did suggest the ability to prognosti-
cate in a small, heterogeneous study, in our study
including this more uniform high-risk population, in
which the use of a biomarker would arguably be most
useful, SPARC did not prove to be informative.
Compared with other malignancies, there is limited
data on SPARC expression in sarcoma, and there is no
uniformly accepted determinant of high vs. low expres-
sion. A recent large study of a varied group of 2539 bone
and soft tissue sarcoma specimens evaluated SPARC
expression by IHC using a cutoff of ≥ 2+ and ≥ 30 % for
positivity. SPARC overexpression was seen in 35.9 % of
the cases, with the highest percentages in epithelioid
hemangioendothelioma, conventional chondrosarcoma,
and angiosarcoma. In this study, no clinical information
in terms of treatment, extent of disease, or survival was
reported [12]. This report raised the possibility of
increased SPARC expression in vascular sarcomas as
compared to other sarcoma subtypes but did not com-
ment on its prognostic or predictive value.
Another study, focused solely on osteosarcoma
patients, evaluated SPARC by quantitative real-time
PCR in initial diagnostic biopsies, primary resections,
and metastatic disease. High SPARC expression was
found in the majority of specimens, 51/55 (96.3 %) and
correlated with a poorer event free-survival (p = 0.03)
and relapse free survival (p = 0.07). There was no differ-
ence in OS [13]. These findings suggest a potential role
Fig. 1 SPARC expression in 3 post-chemotherapy, primary
resection patients
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for SPARC as a prognostic biomarker in osteosarcoma,
although with the majority of patients expressing
SPARC, the clinical implications are unclear. Similar to
our results in soft tissue sarcoma, SPARC overexpres-
sion in osteosarcoma did not correlate with different
time points of specimen collection (biopsy, surgical
resection, and metastasis) or clinical and pathological
variables such as age, gender, histology, or site of
primary disease.
Because SPARC mediates albumin transport, it may
facilitate entry of albumin-bound paclitaxel into the
tumor cells [3]. This has led to studies in various
malignancies evaluating the efficacy of nanoparticle
albumin-bound (nab)-paclitaxel based upon SPARC
expression with correlation in response rates in high
SPARC expressers in head and neck cancer patients
[14] but inconsistent results in pancreatic cancer
patients [5]. The evaluation of efficacy of nab-paclitaxel
in sarcoma has thus far been limited to one small phase
II study of 15 assessable patients [15]. Various subtypes
were included and SPARC expression was not assessed,
and given the small sample size and heterogeneity of
tumor types, no conclusions as to the efficacy of nab-
paclitaxel in sarcoma could be drawn from this study.
Fig. 2 Recurrence-free survival by SPARC expression in primary tumors, none versus any SPARC
Fig. 3 Overall survival by SPARC expression in primary tumors, none versus any SPARC
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Preclinical work in xenograft models of osteosarcoma and
Ewing’s sarcoma has demonstrated inhibition of tumor
growth by nab-paclitaxel [16]. As nab-paclitaxel or other
chemotherapy agents that bind to albumin such as aldox-
orubicin are evaluated in sarcoma, the use of SPARC as a
predictive biomarker might be considered.
There were limitations to our study. The small sample
size precludes adequate power to detect differences in
SPARC expression between the various subtypes of sar-
coma. There also were no vascular or bone sarcomas in
our dataset which may be subtypes for which SPARC has
higher prognostic potential. Our data are also limited in
that nearly all samples were post-chemotherapy, and it is
entirely possible that chemotherapy changes SPARC ex-
pression levels [17]. It is also conceivable that the treat-
ment rendered on clinical study influenced patient
outcomes independent of SPARC expression. In an
optimal setting, SPARC expression would be deter-
mined pre and post-treatment in order to discern its
prognostic and predictive significance. The optimal
SPARC antibody also needs to be determined as the
studies performed thus far have used different anti-
bodies. Standardized scoring of SPARC expression
and defining what constitutes overexpression is also
important for the design of subsequent work. Future
studies might focus on prospective evaluation of
SPARC expression in sarcoma, especially in a cohort
of patients treated with albumin-bound agents.
Conclusions
In conclusion, while this study found a trend toward im-
proved time to recurrence and OS in patients with high-
grade soft tissue sarcoma whose tumors lacked SPARC
expression, SPARC did not demonstrate the ability to
discern which high-risk patients may have a worse prog-
nosis or a greater benefit from chemotherapy.
Additional file
Additional file 1: Table S1. Multivariate model for OS by SPARC
expression, any versus no expression. Table S2. Multivariate model for
time to recurrence by SPARC expression, any versus no expression. Table
S3. Distribution of SPARC scores. (DOCX 15 kb)
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